10:05 AM EST, 11/15/2024 (MT Newswires) -- CERo Therapeutics Holdings ( CERO ) said Friday that the US Food and Drug Administration has cleared its investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.

The company said it expects to start the phase 1 trial in Q1 of 2025.

CERo's shares soared past 79% in recent trading.

Price: 0.34, Change: +0.15, Percent Change: +79.22